Current and future pharmacological treatment strategies with regard to aortic disease in Marfan syndrome

Bibliography

• Judge DP, Dietz HC. Marfan's syndrome. Lancet 2005;366(9501):1965-76
   PubMed Web of Science ®Google Scholar
• Arslan-Kirchner M, Arbustini E, Boileau C, Clinical utility gene card for: Marfan syndrome type 1 and related phenotypes [FBN1]. Eur J Hum Genet 2010;18:(9). doi: 10.1038/ejhg.2010.42. [Epub April 7 2010]
   PubMed Web of Science ®Google Scholar
• Loeys B, Nuytinck L, Delvaux I, Genotype and phenotype analysis of 171 patients referred for molecular study of the fibrillin-1 gene FBN1 because of suspected Marfan syndrome. Arch Intern Med 2001;161(20):2447-54
   PubMedGoogle Scholar
• De PA, Devereux RB, Dietz HC, Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996;62(4):417-26
   PubMedGoogle Scholar
• Loeys BL, Dietz HC, Braverman AC, The revised Ghent nosology for the Marfan syndrome. J Med Genet 2010;47(7):476-85
   PubMed Web of Science ®Google Scholar
• Faivre L, Collod-Beroud G, Ades L, The new Ghent criteria for Marfan syndrome: what do they change? Clin Genet 2011; doi: 10.1111/j.1399-0004.2011.01703.x. [Epub ahead of print]
   Google Scholar
• Milewicz DM, Dietz HC, Miller DC. Treatment of aortic disease in patients with Marfan syndrome. Circulation 2005;111(11):e150-7
   PubMedGoogle Scholar
• Faivre L, Collod-Beroud G, Loeys BL, Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am J Hum Genet 2007;81(3):454-66
   PubMed Web of Science ®Google Scholar
• van Karnebeek CD, Naeff MS, Mulder BJ, Natural history of cardiovascular manifestations in Marfan syndrome. Arch Dis Child 2001;84(2):129-37
   PubMed Web of Science ®Google Scholar
• Chen S, Fagan LF, Nouri S, Ventricular dysrhythmias in children with Marfan's syndrome. Am J Dis Child 1985;139(3):273-6
   PubMedGoogle Scholar
• Yetman AT, Bornemeier RA, McCrindle BW. Long-term outcome in patients with Marfan syndrome: is aortic dissection the only cause of sudden death? J Am Coll Cardiol 2003;41(2):329-32
   PubMed Web of Science ®Google Scholar
• Chen S, Fagan LF. Wolff-Parkinson-White syndrome in Marfan's syndrome. J Pediatr 1974;84(2):302
   PubMedGoogle Scholar
• Yetman AT, Temple J, Erickson CC. Radiofrequency ablation of a left-sided atrioventricular pathway in a patient with Marfan syndrome. Cardiol Young 2002;12(5):494-5
   PubMedGoogle Scholar
• Meijboom LJ, Timmermans J, van Tintelen JP, Evaluation of left ventricular dimensions and function in Marfan's syndrome without significant valvular regurgitation. Am J Cardiol 2005;95(6):795-7
   PubMed Web of Science ®Google Scholar
• de WP, Aalberts JJ, Radonic T, Intrinsic biventricular dysfunction in Marfan syndrome. Heart 2011;97(24):2063-8
   PubMedGoogle Scholar
• Das BB, Taylor AL, Yetman AT. Left ventricular diastolic dysfunction in children and young adults with Marfan syndrome. Pediatr Cardiol 2006;27(2):256-8
   PubMedGoogle Scholar
• Pyeritz RE, Wappel MA. Mitral valve dysfunction in the Marfan syndrome. Clinical and echocardiographic study of prevalence and natural history. Am J Med 1983;74(5):797-807
   PubMed Web of Science ®Google Scholar
• Roberts WC, Honig HS. The spectrum of cardiovascular disease in the Marfan syndrome: a clinico-morphologic study of 18 necropsy patients and comparison to 151 previously reported necropsy patients. Am Heart J 1982;104(1):115-35
   PubMed Web of Science ®Google Scholar
• Hirata K, Triposkiadis F, Sparks E, The Marfan syndrome: abnormal aortic elastic properties. J Am Coll Cardiol 1991;18(1):57-63
   PubMed Web of Science ®Google Scholar
• Groenink M, de RA, Mulder BJ, Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. Am J Cardiol 1998;82(2):203-8
   PubMed Web of Science ®Google Scholar
• Jeremy RW, Huang H, Hwa J, Relation between age, arterial distensibility, and aortic dilatation in the Marfan syndrome. Am J Cardiol 1994;74(4):369-73
   PubMed Web of Science ®Google Scholar
• Detaint D, Faivre L, Collod-Beroud G, Cardiovascular manifestations in men and women carrying a FBN1 mutation. Eur Heart J 2010;31(18):2223-9
   PubMedGoogle Scholar
• Taub CC, Stoler JM, Perez-Sanz T, Mitral valve prolapse in Marfan syndrome: an old topic revisited. Echocardiography 2009;26(4):357-64
   PubMedGoogle Scholar
• Morse RP, Rockenmacher S, Pyeritz RE, Diagnosis and management of infantile marfan syndrome. Pediatrics 1990;86(6):888-95
   PubMed Web of Science ®Google Scholar
• Sisk HE, Zahka KG, Pyeritz RE. The Marfan syndrome in early childhood: analysis of 15 patients diagnosed at less than 4 years of age. Am J Cardiol 1983;52(3):353-8
   PubMed Web of Science ®Google Scholar
• Faivre L, Masurel-Paulet A, Collod-Beroud G, Clinical and molecular study of 320 children with Marfan syndrome and related type 1 fibrillinopathies in a series of 1009 probands with pathogenic FBN1 mutations. Pediatrics 2009;123(1):391-8
   PubMedGoogle Scholar
• Silverman DI, Burton KJ, Gray J, Life expectancy in the Marfan syndrome. Am J Cardiol 1995;75(2):157-60
   PubMed Web of Science ®Google Scholar
• Carr JA, Savage EB. Aortic valve repair for aortic insufficiency in adults: a contemporary review and comparison with replacement techniques. Eur J Cardiothorac Surg 2004;25(1):6-15
   PubMedGoogle Scholar
• David TE. Aortic valve repair for management of aortic insufficiency. Adv Card Surg 1999;11:129-59
   PubMedGoogle Scholar
• El KG, Vanoverschelde JL, Glineur D, Repair of aortic valve prolapse: experience with 44 patients. Eur J Cardiothorac Surg 2004;26(3):628-33
   PubMedGoogle Scholar
• El KG, Vanoverschelde JL, Glineur D, Repair of bicuspid aortic valves in patients with aortic regurgitation. Circulation 2006;114(1 Suppl):I610-16
   PubMedGoogle Scholar
• Langer F, Graeter T, Nikoloudakis N, Valve-preserving aortic replacement: does the additional repair of leaflet prolapse adversely affect the results? J Thorac Cardiovasc Surg 2001;122(2):270-7
   PubMedGoogle Scholar
• Lausberg HF, Aicher D, Langer F, Aortic valve repair with autologous pericardial patch. Eur J Cardiothorac Surg 2006;30(2):244-9
   PubMedGoogle Scholar
• Schafers HJ, Aicher D, Langer F. Correction of leaflet prolapse in valve-preserving aortic replacement: pushing the limits? Ann Thorac Surg 2002;74(5):S1762-4
   PubMed Web of Science ®Google Scholar
• Minakata K, Schaff HV, Zehr KJ, Is repair of aortic valve regurgitation a safe alternative to valve replacement? J Thorac Cardiovasc Surg 2004;127(3):645-53
   PubMedGoogle Scholar
• le Polain de Waroux JB, Pouleur AC, Robert A, Mechanisms of recurrent aortic regurgitation after aortic valve repair: predictive value of intraoperative transesophageal echocardiography. JACC Cardiovasc Imaging 2009;2(8):931-9
   PubMedGoogle Scholar
• Engelfriet PM, Boersma E, Tijssen JG, Beyond the root: dilatation of the distal aorta in Marfan's syndrome. Heart 2006;92(9):1238-43
   PubMedGoogle Scholar
• Mulder BJ. The distal aorta in the Marfan syndrome. Neth Heart J 2008;16(11):382-6
   PubMed Web of Science ®Google Scholar
• Carlson RG, Lillehei CW, Edwards JE. Cystic medial necrosis of the ascending aorta in relation to age and hypertension. Am J Cardiol 1970;25(4):411-15
   PubMedGoogle Scholar
• Dean JC. Management of Marfan syndrome. Heart 2002;88(1):97-103
   PubMedGoogle Scholar
• Nagashima H, Sakomura Y, Aoka Y, Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan's syndrome. Circulation 2001;104(12 Suppl 1):I282-7
   PubMedGoogle Scholar
• Fedak PW, de Sa MP, Verma S, Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. J Thorac Cardiovasc Surg 2003;126(3):797-806
   PubMed Web of Science ®Google Scholar
• Dingemans KP, Teeling P, Lagendijk JH, Extracellular matrix of the human aortic media: an ultrastructural histochemical and immunohistochemical study of the adult aortic media. Anat Rec 2000;258(1):1-14
   PubMedGoogle Scholar
• Ramirez F, Rifkin DB. Cell signaling events: a view from the matrix. Matrix Biol 2003;22(2):101-7
   PubMed Web of Science ®Google Scholar
• Neptune ER, Frischmeyer PA, Arking DE, Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003;33(3):407-11
   PubMed Web of Science ®Google Scholar
• Habashi JP, Judge DP, Holm TM, Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006;312(5770):117-21
   PubMed Web of Science ®Google Scholar
• Ng CM, Cheng A, Myers LA, TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 2004;114(11):1586-92
   PubMed Web of Science ®Google Scholar
• Pueyo ME, Michel JB. Angiotensin II receptors in endothelial cells. Gen Pharmacol 1997;29(5):691-6
   PubMedGoogle Scholar
• Dikalova A, Clempus R, Lassegue B, Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005;112(17):2668-76
   PubMed Web of Science ®Google Scholar
• Rueckschloss U, Quinn MT, Holtz J, Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2002;22(11):1845-51
   PubMedGoogle Scholar
• Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000;105(11):1605-12
   PubMed Web of Science ®Google Scholar
• Su EJ, Lombardi DM, Siegal J, Angiotensin II induces vascular smooth muscle cell replication independent of blood pressure. Hypertension 1998;31(6):1331-7
   PubMedGoogle Scholar
• Lee AA, Dillmann WH, McCulloch AD, Angiotensin II stimulates the autocrine production of transforming growth factor-beta 1 in adult rat cardiac fibroblasts. J Mol Cell Cardiol 1995;27(10):2347-57
   PubMedGoogle Scholar
• Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 2005;111(19):2509-17
   PubMedGoogle Scholar
• Jones ES, Black MJ, Widdop RE. Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade. J Mol Cell Cardiol 2004;37(5):1023-30
   PubMed Web of Science ®Google Scholar
• Akishita M, Ito M, Lehtonen JY, Expression of the AT2 receptor developmentally programs extracellular signal-regulated kinase activity and influences fetal vascular growth. J Clin Invest 1999;103(1):63-71
   PubMedGoogle Scholar
• Ulmasov B, Xu Z, Tetri LH, Protective role of angiotensin II type 2 receptor signaling in a mouse model of pancreatic fibrosis. Am J Physiol Gastrointest Liver Physiol 2009;296(2):G284-94
   PubMedGoogle Scholar
• Habashi JP, Doyle JJ, Holm TM, Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 2011;332(6027):361-5
   PubMed Web of Science ®Google Scholar
• Habashi JP, Doyle JJ, Holm TM, Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 2011;332(6027):361-5
   PubMed Web of Science ®Google Scholar
• Busuttil RW, Abou-Zamzam AM, Machleder HI. Collagenase activity of the human aorta. A comparison of patients with and without abdominal aortic aneurysms. Arch Surg 1980;115(11):1373-8
   PubMedGoogle Scholar
• Busuttil RW, Rinderbriecht H, Flesher A, Elastase activity: the role of elastase in aortic aneurysm formation. J Surg Res 1982;32(3):214-17
   PubMedGoogle Scholar
• Murphy G, Cockett MI, Ward RV, Matrix metalloproteinase degradation of elastin, type 4 collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 1991;277(Pt 1):277-9
   PubMedGoogle Scholar
• Senior RM, Griffin GL, Fliszar CJ, Human 92- and 72-kilodalton type 4 collagenases are elastases. J Biol Chem 1991;266(12):7870-5
   PubMedGoogle Scholar
• Thompson RW, Holmes DR, Mertens RA, Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 1995;96(1):318-26
   PubMed Web of Science ®Google Scholar
• Thompson RW, Parks WC. Role of matrix metalloproteinases in abdominal aortic aneurysms. Ann NY Acad Sci 1996;800:157-74
   PubMed Web of Science ®Google Scholar
• Booms P, Pregla R, Ney A, RGD-containing fibrillin-1 fragments upregulate matrix metalloproteinase expression in cell culture: a potential factor in the pathogenesis of the Marfan syndrome. Hum Genet 2005;116(1-2):51-61
   PubMed Web of Science ®Google Scholar
• Freestone T, Turner RJ, Coady A, Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1995;15(8):1145-51
   PubMedGoogle Scholar
• Longo GM, Xiong W, Greiner TC, Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002;110(5):625-32
   PubMed Web of Science ®Google Scholar
• Davis V, Persidskaia R, Baca-Regen L, Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 1998;18(10):1625-33
   PubMedGoogle Scholar
• Segura AM, Luna RE, Horiba K, Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome. Circulation 1998;98(19 Suppl):II331-7
   PubMedGoogle Scholar
• Bunton TE, Biery NJ, Myers L, Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. Circ Res 2001;88(1):37-43
   PubMed Web of Science ®Google Scholar
• Xiong W, Knispel RA, Dietz HC, Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome. J Vasc Surg 2008;47(1):166-72
   PubMedGoogle Scholar
• Katsuda S, Okada Y, Okada Y, Matrix metalloproteinase-9 (92-kd gelatinase/type 4 collagenase equals gelatinase B) can degrade arterial elastin. Am J Pathol 1994;145(5):1208-18
   PubMedGoogle Scholar
• Chung AW, Au YK, Sandor GG, Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in the thoracic aortic aneurysm in Marfan syndrome. Circ Res 2007;101(5):512-22
   PubMedGoogle Scholar
• Chung AW, Yang HH, van BC. Imbalanced synthesis of cyclooxygenase-derived thromboxane A2 and prostacyclin compromises vasomotor function of the thoracic aorta in Marfan syndrome. Br J Pharmacol 2007;152(3):305-12
   PubMedGoogle Scholar
• Chung AW, Au YK, Cortes SF, Endothelial dysfunction and compromised eNOS/Akt signaling in the thoracic aorta during the progression of Marfan syndrome. Br J Pharmacol 2007;150(8):1075-83
   PubMedGoogle Scholar
• Cecconi M, Nistri S, Quarti A, Aortic dilatation in patients with bicuspid aortic valve. J Cardiovasc Med (Hagerstown) 2006;7(1):11-20
   PubMedGoogle Scholar
• Wheat MW Jr, Palmer RF, Bartley TD, Treatment of dissecting aneurysms of the aorta without surgery. J Thorac Cardiovasc Surg 1965;50:364-73
   PubMed Web of Science ®Google Scholar
• Harris PD, Malm JR, Bigger JT Jr, Follow-up studies of acute dissecting aortic aneurysms managed with antihypertensive agents. Circulation 1967;35(4 Suppl):I183-7
   PubMedGoogle Scholar
• Simpson CF, Kling JM, Palmer RF. Beta-aminopropionitrile-induced dissecting aneurysms of turkeys: treatment with propranolol. Toxicol Appl Pharmacol 1970;16(1):143-53
   PubMedGoogle Scholar
• Halpern BL, Char F, Murdoch JL, A prospectus on the prevention of aortic rupture in the Marfan syndrome with data on survivorship without treatment. Johns Hopkins Med J 1971;129(3):123-9
   PubMedGoogle Scholar
• Ose L, McKusick VA. Prophylactiv use of propranolol in the Marfan syndrome to prevent aortic dissection. Birth Defects Orig Artic Ser 1977;13(3C):163-9
   PubMedGoogle Scholar
• Shores J, Berger KR, Murphy EA, Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 1994;330(19):1335-41
   PubMed Web of Science ®Google Scholar
• Rossi-Foulkes R, Roman MJ, Rosen SE, Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. Am J Cardiol 1999;83(9):1364-8
   PubMed Web of Science ®Google Scholar
• Roman MJ, Rosen SE, Kramer-Fox R, Prognostic significance of the pattern of aortic root dilation in the Marfan syndrome. J Am Coll Cardiol 1993;22(5):1470-6
   PubMed Web of Science ®Google Scholar
• Tahernia AC. Cardiovascular anomalies in Marfan's syndrome: the role of echocardiography and beta-blockers. South Med J 1993;86(3):305-10
   PubMedGoogle Scholar
• Salim MA, Alpert BS, Ward JC, Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. Am J Cardiol 1994;74(6):629-33
   PubMed Web of Science ®Google Scholar
• Gersony DR, McClaughlin MA, Jin Z, The effect of beta-blocker therapy on clinical outcome in patients with Marfan's syndrome: a meta-analysis. Int J Cardiol 2007;114(3):303-8
   PubMed Web of Science ®Google Scholar
• Rios AS, Silber EN, Bavishi N, Effect of long-term beta-blockade on aortic root compliance in patients with Marfan syndrome. Am Heart J 1999;137(6):1057-61
   PubMedGoogle Scholar
• Groenink M, de RA, Mulder BJ, Biophysical properties of the normal-sized aorta in patients with Marfan syndrome: evaluation with MR flow mapping. Radiology 2001;219(2):535-40
   PubMedGoogle Scholar
• Reed CM, Fox ME, Alpert BS. Aortic biomechanical properties in pediatric patients with the Marfan syndrome, and the effects of atenolol. Am J Cardiol 1993;71(7):606-8
   PubMedGoogle Scholar
• Nollen GJ, Westerhof BE, Groenink M, Aortic pressure-area relation in Marfan patients with and without beta blocking agents: a new non-invasive approach. Heart 2004;90(3):314-18
   PubMedGoogle Scholar
• Meijboom LJ, Westerhof BE, Nollen GJ, Beta-blocking therapy in patients with the Marfan syndrome and entire aortic replacement. Eur J Cardiothorac Surg 2004;26(5):901-6
   PubMedGoogle Scholar
• Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol 2005;95(9):1125-7
   PubMed Web of Science ®Google Scholar
• Yin FC, Brin KP, Ting CT, Arterial hemodynamic indexes in Marfan's syndrome. Circulation 1989;79(4):854-62
   PubMedGoogle Scholar
• Haouzi A, Berglund H, Pelikan PC, Heterogeneous aortic response to acute beta-adrenergic blockade in Marfan syndrome. Am Heart J 1997;133(1):60-3
   PubMedGoogle Scholar
• Selamet Tierney ES, Feingold B, Printz BF, Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. J Pediatr 2007;150(1):77-82
   PubMed Web of Science ®Google Scholar
• Ladouceur M, Fermanian C, Lupoglazoff JM, Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. Am J Cardiol 2007;99(3):406-9
   PubMed Web of Science ®Google Scholar
• Manalo-Estrella P, Barker AE. Histopathologic findings in human aortic media associated with pregnancy. Arch Pathol 1967;83(4):336-41
   PubMedGoogle Scholar
• Immer FF, Bansi AG, Immer-Bansi AS, Aortic dissection in pregnancy: analysis of risk factors and outcome. Ann Thorac Surg 2003;76(1):309-14
   PubMed Web of Science ®Google Scholar
• Lipscomb KJ, Smith JC, Clarke B, Outcome of pregnancy in women with Marfan's syndrome. Br J Obstet Gynaecol 1997;104(2):201-6
   PubMedGoogle Scholar
• Meijboom LJ, Vos FE, Timmermans J, Pregnancy and aortic root growth in the Marfan syndrome: a prospective study. Eur Heart J 2005;26(9):914-20
   PubMed Web of Science ®Google Scholar
• Meijboom LJ, Drenthen W, Pieper PG, Obstetric complications in Marfan syndrome. Int J Cardiol 2006;110(1):53-9
   PubMed Web of Science ®Google Scholar
• Mulder BJ, Bleker OP. Valvular heart disease in pregnancy. N Engl J Med 2003;349(14):1387
   PubMedGoogle Scholar
• Pyeritz RE. Maternal and fetal complications of pregnancy in the Marfan syndrome. Am J Med 1981;71(5):784-90
   PubMed Web of Science ®Google Scholar
• Rossiter JP, Repke JT, Morales AJ, A prospective longitudinal evaluation of pregnancy in the Marfan syndrome. Am J Obstet Gynecol 1995;173(5):1599-606
   PubMed Web of Science ®Google Scholar
• Zeebregts CJ, Schepens MA, Hameeteman TM, Acute aortic dissection complicating pregnancy. Ann Thorac Surg 1997;64(5):1345-8
   PubMedGoogle Scholar
• Ferrero S, Colombo BM, Ragni N. Maternal arrhythmias during pregnancy. Arch Gynecol Obstet 2004;269(4):244-53
   PubMedGoogle Scholar
• Yankowitz J. Pharmacologic treatment of hypertensive disorders during pregnancy. J Perinat Neonatal Nurs 2004;18(3):230-40
   PubMedGoogle Scholar
• Yetman AT, Roosevelt GE, Veit N, Distal aortic and peripheral arterial aneurysms in patients with marfan syndrome. J Am Coll Cardiol 2011;58(24):2544-5
   PubMed Web of Science ®Google Scholar
• Engelfriet PM, Boersma E, Tijssen JG, Beyond the root: dilatation of the distal aorta in Marfan's syndrome. Heart 2006;92(9):1238-43
   PubMedGoogle Scholar
• Mulder BJ. The distal aorta in the Marfan syndrome. Neth Heart J 2008;16(11):382-6
   PubMed Web of Science ®Google Scholar
• Detter C, Mair H, Klein HG, Long-term prognosis of surgically-treated aortic aneurysms and dissections in patients with and without Marfan syndrome. Eur J Cardiothorac Surg 1998;13(4):416-23
   PubMedGoogle Scholar
• London GM, Guerin AP. Influence of arterial pulse and reflected waves on blood pressure and cardiac function. Am Heart J 1999;138(3 Pt 2):220-4
   PubMedGoogle Scholar
• Safar ME, Tual JL, Safavian A, Antihypertensive therapy and wave reflections. Prostaglandins Leukot Essent Fatty Acids 1996;54(1):71-6
   PubMedGoogle Scholar
• Ting CT, Chou CY, Chang MS, Arterial hemodynamics in human hypertension. Effects of adrenergic blockade. Circulation 1991;84(3):1049-57
   PubMed Web of Science ®Google Scholar
• Curci JA, Mao D, Bohner DG, Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg 2000;31(2):325-42
   PubMed Web of Science ®Google Scholar
• Ramamurthy NS, Vernillo AT, Greenwald RA, Reactive oxygen species activate and tetracyclines inhibit rat osteoblast collagenase. J Bone Miner Res 1993;8(10):1247-53
   PubMedGoogle Scholar
• Golub LM, Lee HM, Ryan ME, Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998;12(2):12-26
   PubMedGoogle Scholar
• Thompson RW, Baxter BT. MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial. Ann NY Acad Sci 1999;878:159-78
   PubMedGoogle Scholar
• Bartoli MA, Parodi FE, Chu J, Localized administration of doxycycline suppresses aortic dilatation in an experimental mouse model of abdominal aortic aneurysm. Ann Vasc Surg 2006;20(2):228-36
   PubMed Web of Science ®Google Scholar
• Petrinec D, Liao S, Holmes DR, Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 1996;23(2):336-46
   PubMed Web of Science ®Google Scholar
• Holmes DR, Petrinec D, Wester W, Indomethacin prevents elastase-induced abdominal aortic aneurysms in the rat. J Surg Res 1996;63(1):305-9
   PubMedGoogle Scholar
• Mosorin M, Juvonen J, Biancari F, Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 2001;34(4):606-10
   PubMed Web of Science ®Google Scholar
• Chung AW, Yang HH, Radomski MW, Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Circ Res 2008;102(8):e73-85
   PubMedGoogle Scholar
• Curci JA, Petrinec D, Liao S, Pharmacologic suppression of experimental abdominal aortic aneurysms: acomparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg 1998;28(6):1082-93
   PubMedGoogle Scholar
• Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2003;23(3):483-8
   PubMedGoogle Scholar
• Prall AK, Longo GM, Mayhan WG, Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg 2002;35(5):923-9
   PubMed Web of Science ®Google Scholar
• Pyo R, Lee JK, Shipley JM, Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 2000;105(11):1641-9
   PubMed Web of Science ®Google Scholar
• Sheth RA, Maricevich M, Mahmood U. In vivo optical molecular imaging of matrix metalloproteinase activity in abdominal aortic aneurysms correlates with treatment effects on growth rate. Atherosclerosis 2010;212(1):181-7
   PubMedGoogle Scholar
• Sho E, Chu J, Sho M, Continuous periaortic infusion improves doxycycline efficacy in experimental aortic aneurysms. J Vasc Surg 2004;39(6):1312-21
   PubMedGoogle Scholar
• Tedesco MM, Terashima M, Blankenberg FG, Analysis of in situ and ex vivo vascular endothelial growth factor receptor expression during experimental aortic aneurysm progression. Arterioscler Thromb Vasc Biol 2009;29(10):1452-7
   PubMedGoogle Scholar
• Turner GH, Olzinski AR, Bernard RE, In vivo serial assessment of aortic aneurysm formation in apolipoprotein E-deficient mice via MRI. Circ Cardiovasc Imaging 2008;1(3):220-6
   PubMedGoogle Scholar
• Vinh A, Gaspari TA, Liu HB, A novel histone deacetylase inhibitor reduces abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. J Vasc Res 2008;45(2):143-52
   PubMedGoogle Scholar
• Yang HH, Kim JM, Chum E, Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome. J Thorac Cardiovasc Surg 2010;140(2):305-12
   PubMedGoogle Scholar
• Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008;75(2):346-59
   PubMed Web of Science ®Google Scholar
• Chew DK, Conte MS, Khalil RA. Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction. J Vasc Surg 2004;40(5):1001-10
   PubMedGoogle Scholar
• Dodd BR, Spence RA. Doxycycline inhibition of abdominal aortic aneurysm growth - a systematic review of the literature. Curr Vasc Pharmacol 2011;9(4):471-8
   PubMedGoogle Scholar
• Crisby M, Nordin-Fredriksson G, Shah PK, Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001;103(7):926-33
   PubMed Web of Science ®Google Scholar
• Yu Y, Ohmori K, Chen Y, Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type 2 diabetes model. J Am Coll Cardiol 2004;44(4):904-13
   PubMedGoogle Scholar
• Ejiri J, Inoue N, Tsukube T, Oxidative stress in the pathogenesis of thoracic aortic aneurysm: protective role of statin and angiotensin II type 1 receptor blocker. Cardiovasc Res 2003;59(4):988-96
   PubMed Web of Science ®Google Scholar
• Sukhija R, Aronow WS, Sandhu R, Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 2006;97(2):279-80
   PubMed Web of Science ®Google Scholar
• Ferguson CD, Clancy P, Bourke B, Association of statin prescription with small abdominal aortic aneurysm progression. Am Heart J 2010;159(2):307-13
   PubMed Web of Science ®Google Scholar
• McLoughlin D, McGuinness J, Byrne J, Pravastatin reduces Marfan aortic dilation. Circulation 2011;124(11 Suppl):S168-73
   PubMedGoogle Scholar
• Izzo JL Jr, Weir MR. Angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich) 2011;13(9):667-75
   PubMed Web of Science ®Google Scholar
• Peng H, Carretero OA, Vuljaj N, Angiotensin-converting enzyme inhibitors: a new mechanism of action. Circulation 2005;112(16):2436-45
   PubMed Web of Science ®Google Scholar
• Hadi HA, Carr CS, Al SJ. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 2005;1(3):183-98
   PubMedGoogle Scholar
• Ahimastos AA, Aggarwal A, D'Orsa KM, Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. JAMA 2007;298(13):1539-47
   PubMed Web of Science ®Google Scholar
• Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997;95(5):1115-18
   PubMedGoogle Scholar
• Yang HY, Erdos EG, Levin Y. Characterization of a dipeptide hydrolase (kininase II: angiotensin I converting enzyme). J Pharmacol Exp Ther 1971;177(1):291-300
   PubMedGoogle Scholar
• Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol 2005;95(9):1125-7
   PubMed Web of Science ®Google Scholar
• Liao S, Miralles M, Kelley BJ, Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg 2001;33(5):1057-64
   PubMed Web of Science ®Google Scholar
• Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet 2006;368(9536):659-65
   PubMed Web of Science ®Google Scholar
• Genoni M, Paul M, Tavakoli R, Predictors of complications in acute type B aortic dissection. Eur J Cardiothorac Surg 2002;22(1):59-63
   PubMedGoogle Scholar
• Glower DD, Fann JI, Speier RH, Comparison of medical and surgical therapy for uncomplicated descending aortic dissection. Circulation 1990;82(5 Suppl):IV39-46
   PubMedGoogle Scholar
• Glower DD, Speier RH, White WD, Management and long-term outcome of aortic dissection. Ann Surg 1991;214(1):31-41
   PubMedGoogle Scholar
• Neya K, Omoto R, Kyo S, Outcome of Stanford type B acute aortic dissection. Circulation 1992;86(5 Suppl):II1-7
   PubMedGoogle Scholar
• Sueyoshi E, Sakamoto I, Hayashi K, Growth rate of aortic diameter in patients with type B aortic dissection during the chronic phase. Circulation 2004;110(11 Suppl 1):II256-61
   PubMedGoogle Scholar
• Takeshita S, Sakamoto S, Kitada S, Angiotensin-converting enzyme inhibitors reduce long-term aortic events in patients with acute type B aortic dissection. Circ J 2008;72(11):1758-61
   PubMed Web of Science ®Google Scholar
• Brooke BS, Habashi JP, Judge DP, Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008;358(26):2787-95
   PubMed Web of Science ®Google Scholar
• Nistala H, Lee-Arteaga S, Carta L, Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. Hum Mol Genet 2010;19(24):4790-8
   PubMed Web of Science ®Google Scholar
• Wilkinson IB, Qasem A, McEniery CM, Nitric oxide regulates local arterial distensibility in vivo. Circulation 2002;105(2):213-17
   PubMed Web of Science ®Google Scholar
• Chung AW, Au YK, Cortes SF, Endothelial dysfunction and compromised eNOS/Akt signaling in the thoracic aorta during the progression of Marfan syndrome. Br J Pharmacol 2007;150(8):1075-83
   PubMedGoogle Scholar
• Nakamura M, Itoh S, Makita S, Peripheral resistance vessel dysfunction in Marfan syndrome. Am Heart J 2000;139(4):661-6
   PubMedGoogle Scholar
• Current controlled trials. The effect of angiotensin 2 blockade and long acting nitrates on arterial stiffness in patients with marfan syndrome. A placebo controlled studt. (ISRCTN 28168217)
   Google Scholar
• Danyi P, Elefteriades JA, Jovin IS. Medical therapy of thoracic aortic aneurysms: are we there yet? Circulation 2011;124(13):1469-76
   PubMed Web of Science ®Google Scholar